134 related articles for article (PubMed ID: 16877721)
1. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
Kulke MH; Bergsland EK; Ryan DP; Enzinger PC; Lynch TJ; Zhu AX; Meyerhardt JA; Heymach JV; Fogler WE; Sidor C; Michelini A; Kinsella K; Venook AP; Fuchs CS
J Clin Oncol; 2006 Aug; 24(22):3555-61. PubMed ID: 16877721
[TBL] [Abstract][Full Text] [Related]
2. Testing the efficacy of antiangiogenic agents in advanced neuroendocrine tumors.
Beltran-Fabregat M; Velasco-Capellas M; Menendez JA
J Clin Oncol; 2007 Jun; 25(18):2624; author reply 2624-5. PubMed ID: 17577045
[No Abstract] [Full Text] [Related]
3. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors.
Zhu LP; Xing J; Wang QX; Kou L; Li C; Hu B; Wu ZW; Wang JJ; Xu GX
Eur J Pharmacol; 2009 Sep; 617(1-3):23-7. PubMed ID: 19615993
[TBL] [Abstract][Full Text] [Related]
4. [Clinical tolerance trial on recombinant human endostatin adenovirus].
Cao Y; Li S; Li HL; Li YH; Zhang DS; Guo Y; Li XL; Lin XB; Huang WL; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):856-60. PubMed ID: 17697547
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
6. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
Eder JP; Supko JG; Clark JW; Puchalski TA; Garcia-Carbonero R; Ryan DP; Shulman LN; Proper J; Kirvan M; Rattner B; Connors S; Keogan MT; Janicek MJ; Fogler WE; Schnipper L; Kinchla N; Sidor C; Phillips E; Folkman J; Kufe DW
J Clin Oncol; 2002 Sep; 20(18):3772-84. PubMed ID: 12228197
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of pretreatment serum level of endostatin to posttreatment distant metastasis in patients with advanced nasopharyngeal carcinoma].
Zhao ZJ; Mo HY; Zhang CQ; Qi B; Li J; Hong MH; Mai HQ
Ai Zheng; 2007 Nov; 26(11):1243-7. PubMed ID: 17991326
[TBL] [Abstract][Full Text] [Related]
9. [Studies on antitumor activity of rhEndostatin].
Li HY; Li Y; Liu ZH; Wu HJ; Chen FH; Chen XG
Yao Xue Xue Bao; 2002 Oct; 37(10):763-6. PubMed ID: 12567857
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
11. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment.
Xu F; Ma Q; Sha H
Crit Rev Ther Drug Carrier Syst; 2007; 24(5):445-92. PubMed ID: 18197781
[TBL] [Abstract][Full Text] [Related]
12. Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin.
Hu B; Zhu HW; Zhu LP; Li C; Rong ZG; Xu JM; Wu ZW; Wang JJ; Xu GX
Acta Pharmacol Sin; 2008 Nov; 29(11):1357-69. PubMed ID: 18954531
[TBL] [Abstract][Full Text] [Related]
13. Clinical and in vitro studies of imatinib in advanced carcinoid tumors.
Yao JC; Zhang JX; Rashid A; Yeung SC; Szklaruk J; Hess K; Xie K; Ellis L; Abbruzzese JL; Ajani JA
Clin Cancer Res; 2007 Jan; 13(1):234-40. PubMed ID: 17200360
[TBL] [Abstract][Full Text] [Related]
14. A quantitative method for measuring the antitumor potency of recombinant human endostatin in vivo.
Xu YF; Zhu LP; Hu B; Rong ZG; Zhu HW; Xu JM; Wu ZW; Wang JJ; Xu GX
Eur J Pharmacol; 2007 Jun; 564(1-3):1-6. PubMed ID: 17346697
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients].
Qin J; Zhang PH; Qian XY; Kang SJ; Luo RC; Wang YG
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):930-2. PubMed ID: 18583230
[TBL] [Abstract][Full Text] [Related]
16. Endostatin therapy reveals a U-shaped curve for antitumor activity.
Tjin Tham Sjin RM; Naspinski J; Birsner AE; Li C; Chan R; Lo KM; Gillies S; Zurakowski D; Folkman J; Samulski J; Javaherian K
Cancer Gene Ther; 2006 Jun; 13(6):619-27. PubMed ID: 16456550
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
19. Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial.
Wang X; Shi Y; Jia Y; Zhao W; Zhang L; Bai G; Ren Y; Chen YZ; Tong Z
Technol Cancer Res Treat; 2021; 20():15330338211064434. PubMed ID: 34931914
[No Abstract] [Full Text] [Related]
20. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
